Enveric Biosciences, Inc. (ENVB) stock
ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.52+0.03 (+2.01%)
Close on Nov 12, 2026Market cap $6.80MP/E –Yield –
Enveric Biosciences operating margin
Operating margin is operating income as a percentage of revenue.
Enveric Biosciences's operating margin for the twelve months ending Sep 30, 2020 was -0.1%. For fiscal 2019 it was -5.8%, against -16.6% the year before. The highest annual figure on record is -3.9% in fiscal 2015.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | -5.8% | +10.9 |
| FY2018 | Dec 31, 2018 | -16.6% | +5.8 |
| FY2017 | Dec 31, 2017 | -22.4% | −7.5 |
| FY2016 | Dec 31, 2016 | -14.9% | −11.0 |
| FY2015 | Dec 31, 2015 | -3.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2020 | Sep 30, 2020 | -5.8% | +11.3 |
| Q2 FY2020 | Jun 30, 2020 | -9.3% | +4.1 |
| Q1 FY2020 | Mar 31, 2020 | -8.7% | +3.4 |
| Q4 FY2019 | Dec 31, 2019 | 22.5% | +127.6 |
| Q3 FY2019 | Sep 30, 2019 | -17.1% | −74.8 |
| Q2 FY2019 | Jun 30, 2019 | -13.4% | −3.7 |
| Q1 FY2019 | Mar 31, 2019 | -12.1% | +0.2 |
| Q4 FY2018 | Dec 31, 2018 | -105.0% | −77.0 |
| Q3 FY2018 | Sep 30, 2018 | 57.7% | +89.2 |
| Q2 FY2018 | Jun 30, 2018 | -9.7% | +18.8 |
| Q1 FY2018 | Mar 31, 2018 | -12.4% | −7.2 |
| Q4 FY2017 | Dec 31, 2017 | -28.0% | −10.5 |
| Q3 FY2017 | Sep 30, 2017 | -31.5% | −18.6 |
| Q2 FY2017 | Jun 30, 2017 | -28.6% | – |
| Q1 FY2017 | Mar 31, 2017 | -5.1% | – |
| Q4 FY2016 | Dec 31, 2016 | -17.5% | – |
| Q3 FY2016 | Sep 30, 2016 | -12.8% | – |
See a number that looks wrong?